Objective: Systemic chemotherapy is an important treatment modality for metastatic hepatocellular carcinoma (HCC); however, the predictive factors of outcome and tumor response have not been fully investigated. The aim of this study was to identify factors that could be used to predict outcome and tumor response to systemic chemotherapy in patients with metastatic HCC. Methods: We retrospectively examined 82 consecutive patients with metastatic HCC undergoing systemic chemotherapy to investigate factors associated with outcome and tumor response. The patients underwent 5-fluorouracil, mitoxantrone and cisplatin (FMP) therapy. Results: The overall objective response rate was 22% (95% confidence interval, 14 -32), and the median survival time and 1-year survival for all patients were 11.2 months and 43.5%, respectively. Multivariate analysis demonstrated that the absence of radiologically active intrahepatic disease (P ¼ 0.02) and ascites (P ¼ 0.002) was independent favorable prognostic factors. Although multivariate analysis revealed no significant predictive factors of tumor response, the response rates in patients without radiologically active intrahepatic disease (response rate, 46%) tended to be higher than those in patients with active intrahepatic disease (response rate, 17%) (P ¼ 0.05). Conclusion: Patients with metastatic HCC, who had sufficient hepatic function and no radiologically active intrahepatic disease, might be good candidates for systemic chemotherapy.
INTRODUCTION
The prognosis of patients with advanced hepatocellular carcinoma (HCC) remains poor, particularly for those with extrahepatic metastases (1) . For patients with extrahepatic disease, systemic chemotherapy is one of the most important treatment modalities (2 -6) , but it has only limited value in clinical practice. Various clinical trials conducted after 1980s using different single agents reported overall response rates of 0 -20%. Combination chemotherapy with cytotoxic agents yields higher response rates (2 -7); however, a randomized controlled study comparing a promising combination therapy with a single agent failed to show any overall survival advantage (8) . Recently, attention has focussed on molecularly targeted agents for the treatment of advanced HCC, because they have been reported to offer some degree of success for the treatment of challenging cancers like renal cell carcinoma (6, 9, 10) . Among them, sorafenib, which is an oral multikinase inhibitor targeting Raf kinase and receptor tyrosine kinases, has been reported to confer an overall survival advantage of 12 weeks, with manageable toxicity, in comparison with placebo in a Phase III trial (11) . These encouraging results suggest that sorafenib promise as a standard treatment for patients with advanced HCC. Recently, combination therapy using sorafenib with cytotoxic agents or other newly developed molecularly targeted agents have been tested for the activity against HCC (6, 10) .
Analysis of predictive factors of outcome and tumor response can suggest the appropriate candidates for systemic chemotherapy. Although those in patients with advanced HCC, not limited to metastatic disease, have often been reported (12 -18) , these factors have not been investigated in patients with metastatic HCC receiving systemic chemotherapy. Since there may be some differences in predictive factors of outcome and tumor response between the patients with metastatic HCC alone and those with advanced HCC partially, including metastatic disease, the present study was conducted to evaluate a number of variables that may affect survival and tumor response in patients with metastatic HCC alone treated by systemic chemotherapy. To our knowledge, this is the first report concerning predictive factors of outcome and tumor response in patients with metastatic HCC alone receiving systemic chemotherapy.
PATIENTS AND METHODS

PATIENTS
The study subjects were 82 consecutive patients with metastatic HCC for whom surgical resection was not indicated, and who underwent continuous infusion of 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) between September 1993 and January 2005 at the National Cancer Center Hospital, Tokyo, Japan ( Table 1 ). The FMP therapy has been reported to show promising anti-tumor activity (response rate: 27%, median survival time: 11.6 months) with tolerable toxicity in a Phase II trial (19) . HCC was diagnosed on the basis of histological examination or distinctive findings of computed tomography (CT) and/or angiography, along with the elevated levels of serum alpha-fetoprotein (AFP) or protein induced by vitamin K absence or antagonist-II (PIVKA II). Pretreatment evaluation included a complete medical history and a physical examination. The laboratory procedures included a complete differential blood count, biochemistry tests, viral markers including serum hepatitis B surface antigen and serum hepatitis C antibody, urinalysis and tumor markers including serum levels of AFP and PIVKA II. All patients underwent electrocardiography, chest radiography and CT/magnetic resonance imaging within 4 weeks before chemotherapy. Written informed consent was obtained from all patients before treatment.
TREATMENT SCHEDULE
All patients received systemic chemotherapy using the FMP regimen as follows: 5-fluorouracil, mitoxantrone and cisplatin were given as a continuous intravenous infusion at a dose of 450 mg/m 2 on Days 1 -5, 6 mg/m 2 on Day 1 and 80 mg/m 2 over a 2-h period on Day 1, respectively, with standard hydration. If there was no evidence of tumor progression or unacceptable toxicity with dose adjustments based on the toxic effects observed, the treatment was repeated every 4 weeks until a maximum of six courses were achieved. The patients who were refractory to this regimen 
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Predictive factors of chemotherapy for HCC were allowed to undergo other anticancer treatments at their physician's discretion.
FACTORS ANALYZED
Pretreatment clinical variables were evaluated for their relationship to the survival and tumor response by univariate and multivariate analyses. The pretreatment variables were chosen by considering possible effects on the prognosis and tumor response as indicated by previous investigations (2 -6,12 -18) or suggested from our own clinical experience. Each variable, which was classified as host-or tumor-related, was divided into two subgroups in accordance with clinically meaningful values as given in Table 2 .
No radiologically active intrahepatic disease was defined as complete tumor necrosis and no residual lesion in the entire liver as a result of prior local therapy on contrastenhanced CT or magnetic resonance imaging before FMP therapy.
Overall survival was measured from the date of initial treatment to the date of death or last follow-up. The objective tumor response was assessed by CT or magnetic resonance imaging every 4 weeks after the start of FMP therapy. Response was evaluated according to the World Health Organization guidelines. The best overall response was recorded for each patient. Bone metastases were not regarded as measurable lesions.
STATISTICAL ANALYSES
Survival curves were calculated by the Kaplan -Meier method, and the differences in survival were evaluated by log-rank test. The Cox proportional hazard model was used to determine the most significant variables related to survival. Differences in response rate were evaluated by the chi-squared test as univariate analyses. The logistic regression model was used to determine the most significant variables related to tumor response. In the multivariate analyses, all variables considered in univariate analysis were entered, and variable selection was not conducted. Statistical analyses were performed using SPSS 11.0J (SPSS Inc. Chicago, IL, USA). All P values presented in this report are of the two-tailed type. Differences at P 0.05 were considered significant.
RESULTS
PATIENT CHARACTERISTICS
The characteristics of all 82 patients are given in Table 1 . The diagnosis of HCC was made on the basis of either histological examination (71 patients, 87%) or distinctive findings of CT and/or angiography with elevated serum levels of AFP or PIVKA II (11 patients, 13%). Prior treatments included hepatic resection in 53 patients (65%), local ablative therapy in 18 (22%), transcatheter arterial chemoembolization in 50 (61%) and no treatment in 13 (16%). Thirteen patients (16%) had been judged as having no active intrahepatic disease radiologically by two radiologists, and their prior treatments for the primary tumor had been hepatic resection in 12 patients, radiofrequency ablation therapy in one, percutaneous ethanol injection in one and transcatheter arterial chemoembolization in two. The median period between the latest prior treatment and the start of FMP therapy was 4.1 (range: 1.1 -51.7) months. The median number of courses of FMP therapy was 2 (range: 1 -6).
SURVIVAL AND TUMOR RESPONSE
The median survival time, 1-year survival proportion and median progression-free survival in all 82 patients were 11.2 months, 43.5%, 3.2 months, respectively ( Fig. 1 ). At the time of analysis, 70 patients had died, and the causes of death were tumor progression and/or hepatic decompensation (65 patients), rupture of esophageal varices (one patient), cerebral bleeding from brain metastasis (three patients) and treatment-related death (one patient).
Eighty-one patients were evaluable for response; the remaining one patient could not be evaluated because of treatment-related death on Day 22 of the first course of FMP therapy. Although no patient achieved a complete response, 18 patients achieved a partial response, giving an overall response rate of 22% (95% confidence interval, 14 -32). Forty-two patients (51%) showed no change and the remaining 21 patients (26%) had progressive disease. The median survivals of the patients with partial response, no change and progressive disease were 22.3, 11.9 and 5.5 months, respectively (P , 0.01). After this chemotherapy, two partial responders underwent surgical resection for residual HCC lesions in the lung and liver, respectively. These resections were successful and both patients achieved complete clinical remission after surgery, and one of both has survived with no recurrence over 7.5 years although the remaining had died of hepatic failure 3 months after resection.
PROGNOSTIC FACTORS
Median survival times, hazard ratios and P values of survival time for univariate analysis are given in Table 2 . Among host-related factors, absence of ascites and an alkaline phosphatase level of 333 U/l were significantly associated with longer survival times. Among tumor-related factors, absence of lymph node metastasis and active intrahepatic disease was significantly associated with longer survival times. The results of multivariate analysis are given in Table 3 . Absence of active intrahepatic disease and ascites was shown by multivariate analysis to be significantly favorable prognostic factors. The overall survival of patients without active intrahepatic disease (median: 22.3 months) was significantly better than that of patients with active intrahepatic disease (median: 10.6 months) (Fig. 2) . The overall survival of Jpn J Clin Oncol 2008;38(10) 677 patients without ascites (median: 11.7 months) was significantly better than that of patients with ascites (median: 2.0 months) ( Fig. 3 ).
PREDICTIVE FACTORS OF TUMOR RESPONSE
The response rates of the two subgroups for each variable are given in Table 2 . Univariate and multivariate analyses revealed no significant predictive factors of tumor response. However, the response rates in patients without active intrahepatic disease in the liver (response rate, 46%) tended to be higher than those in patients with active intrahepatic disease (response rate, 17%) (P ¼ 0.05).
DISCUSSION
Systemic chemotherapy for metastatic HCC is an important treatment modality (2 -6) , especially in view of the verified survival benefit of sorafenib (10, 11) . In this Phase III trial comparing sorafenib with placebo for advanced HCC (11), the rate of response to sorafenib was low (complete response: 0%, partial response: 2.3%), but the time-toprogression and overall survival were significantly longer for sorafenib than for placebo (median time-to-progression: 24.0 versus 12.3 weeks, hazard ratio 0.69, P ¼ 0.000007, overall median survival: 46.3 versus 34.4 weeks, hazard ratio 0.58, P ¼ 0.00058). Sorafenib is the first agent that has been proven to confer a survival benefit, and to show promise as a standard treatment, for patients with advanced HCC (10). To improve the treatment efficacy, development of further regimens of systemic chemotherapy, such as combination therapy comprising sorafenib and cytotoxic agents or other molecularly targeted agents, remains challenging. In this study, to clarify the appropriate candidates for systemic chemotherapy, analysis of predictive outcomes and tumor response was conducted in patients with metastatic HCC receiving systemic chemotherapy. The study subjects were patients with metastatic HCC receiving FMP therapy, which has been shown in a Phase II trial to have promising anti-tumor activity (response rate: 27%, median survival time: 11.6 months) with tolerable toxicity for metastatic HCC (19) . This regimen consists of three kinds of cytotoxic agents, not molecularly targeted agents like sorafenib. There were some differences between conventional cytotoxic chemotherapy and molecularly targeted agents. First, the tumor responses to conventional cytotoxic chemotherapy were greater than for molecularly targeted agents. Secondly, the 
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Predictive factors of chemotherapy for HCC toxicities of conventional cytotoxic chemotherapy, especially hematological and hepatic toxicities, were more severe and difficult to manage than those of molecularly targeted agents. Thirdly, some conventional cytotoxic regimens need to be administered on an inpatient basis with standard hydration. However, many molecularly targeted agents are orally active and can be taken by patients on an outpatient basis. Therefore, there may be some differences in predictive outcome and tumor response between combination therapy comprising cytotoxic agents alone and therapy that includes molecularly targeted agents. Recently, trials of combinations of cytotoxic and molecularly targeted agents have been reported increasingly (10) , and it would be worthwhile to analyze the predictive outcomes and tumor response in these subjects.
Multivariate analysis of prognostic factors in this study showed that absence of ascites and radiologically active intrahepatic disease was independent favorable factors. Presence of ascites is one of the most important factors to consider when evaluating hepatic reserve, being included in the Okuda staging system (20) and Child-Pugh classification (21) and has been shown to be a prognostic factor in previous studies of patients with advanced HCC (3, 12, 18) . Although patients with massive or moderate ascites were not included in the present study, the outcome for patients with even a small amount of ascites was extremely poor, with a median survival of only 2.0 months. In such patients with impaired hepatic reserve, the toxicity of chemotherapy might outweigh its benefits.
There were some possible reasons why patients without active intrahepatic disease showed better survival than those with active intrahepatic disease. First, those without active intrahepatic disease might have a lower risk of hepatic failure due to progression of the intrahepatic tumor compared with those with active intrahepatic disease. Second, they might have a smaller tumor burden than those with active intrahepatic disease. A smaller tumor burden has been reported to be a favorable, independent prognostic indicator for advanced HCC (3, 12, 18) . Finally, they might obtain a better tumor shrinkage effect of FMP therapy compared with patients with active intrahepatic disease, and this in turn might result in longer survival. Therefore, we also analyzed the predictive factors of tumor response to identify patients who might obtain a tumor response to FMP therapy. In patients receiving conventional cytotoxic agents/regimens like FMP therapy, it is important to predict the tumor response, because patients who achieve tumor shrinkage may show prolonged survival and improvement of clinical symptoms, such as tumor-related pain, and their general condition.
Among the variables investigated, the response rates in patients without active intrahepatic disease tended to be higher than those in patients with active intrahepatic disease, although the differences did not reach significance in univariate and multivariate analyses. The response rates in the patients with active intrahepatic disease were also analyzed, but no specific findings were obtained (data not shown). The precise reasons why patients without active intrahepatic disease obtained a better tumor response than those with such lesions remain unknown. There were no differences in patient characteristics, such as performance status, hepatic function, tumor burden outside the liver and tumor markers, between patients with and without active intrahepatic disease. The limited tumor heterogeneity in this population might have been a factor: heterogeneity of HCC has been reported to be closely related to chemoresistance (2 -6,10,22) . Yang et al. (18) have also reported a better response in patients with distant metastases than in those without, the difference perhaps suggesting heterogeneity of intrahepatic HCC. The limited heterogeneity in patients without active intrahepatic disease might result in a better response to FMP therapy. From these analyses of predictive factors of outcome and tumor response in patients with metastatic HCC receiving systemic chemotherapy, the best candidates were considered to be patients without ascites and active intrahepatic disease, although it may be considered that the results merely reflect the patients' conditions classified according to outcome. In such patients, FMP therapy resulted in favorable survival (median: 22.3 months) and tumor response (46%), although such patients comprised a very small population (only 16% in this study). These factors need to be considered in future clinical trials, including randomized trials, for patients with advanced HCC.
In conclusion, patients with metastatic HCC who have sufficient hepatic function and no active intrahepatic disease might be good candidates for systemic chemotherapy. This analysis may be helpful for predicting life expectancy and tumor response, determining treatment strategies and designing future clinical trials, including randomized trials for patients with advanced HCC.
